The stock of Aurinia Pharmaceuticals Inc (TSE:AUP) is a huge mover today! About 64,415 shares traded hands. Aurinia Pharmaceuticals Inc (TSE:AUP) has risen 13.07% since April 8, 2016 and is uptrending. It has outperformed by 8.08% the S&P500.
The move comes after 7 months positive chart setup for the $190.94M company. It was reported on Nov, 14 by Barchart.com. We have $9.33 PT which if reached, will make TSE:AUP worth $194.76 million more.
Another recent and important Aurinia Pharmaceuticals Inc (TSE:AUP) news was published by Businesswire.com which published an article titled: “Aurinia Pharmaceuticals to Present at Stifel 2016 Healthcare Conference” on November 10, 2016.
Aurinia Pharmaceuticals Inc. is a Canada clinical-stage biopharmaceutical firm operating in the field of nephrology and autoimmunity. The company has a market cap of $190.94 million. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis . It currently has negative earnings. It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.